Piper Sandler analyst Edward Tenthoff noted that the FDA has lifted the clinical hold it previously placed on the Phase 2 AML study of Marker Therapeutics' MultiTAA, but has placed a partial hold on the alternative reagent, requesting new data. While it awaits the new data, which should be received in mid 2020. the FDA permitted dosing three patients in the safety lead-in with the legacy reagent, Tenthoff noted. He maintains an Overweight rating on Marker shares, but is trimming his price target on the stock to $5 from $6 due to delay of the Phase 2 AML study.